Skip to main content
SpringerLink
Log in

Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment

  • Teaching Section
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NCI. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute.

  2. IARC. International incidence of childhood cancer, 1998 (IICC-2), vol II, IARC Scientific Publication No 144.

  3. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004;30:269–80.

    Article  PubMed  CAS  Google Scholar 

  4. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123–39.

    PubMed  CAS  Google Scholar 

  5. Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases: a report from the Intergroup Rhabdomyosarcoma Study Committee. Med Pediatr Oncol 1988;16:33–9.

    Article  PubMed  CAS  Google Scholar 

  6. Li FP, Fraumeni JR, Mulvihill JT, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358–62.

    PubMed  CAS  Google Scholar 

  7. Birch JM, Hartley AL, Blair V, et al. Cancer in the families of children with soft tissue sarcoma. Cancer 1990; 66:2239–48.

    Article  PubMed  CAS  Google Scholar 

  8. Bargonetti J, Manfredi JJ. Multiple roles of tumor suppressor p53. Curr Opin Oncol 2002;14:86–91.

    Article  PubMed  CAS  Google Scholar 

  9. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76:1073–85.

    Article  PubMed  Google Scholar 

  10. Coffin C. The new international rhabdomyosarcoma classification, its progenitors and considerations beyond morphology. Adv Anat Pathol 1997;4:1–16.

    Article  Google Scholar 

  11. Loh EWJ, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth supresor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 1992;89:1755–9.

    Article  PubMed  CAS  Google Scholar 

  12. Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization: an Intergroup Rhabdomyosarcoma Study. Genes Chromosome Cancer 2000;27:337–44.

    Article  CAS  Google Scholar 

  13. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483–91.

    Article  PubMed  CAS  Google Scholar 

  14. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736–46.

    Article  PubMed  CAS  Google Scholar 

  15. Anderson J, Gordon A, Pritchard-Jones K, et al. Genes, chromosomes and rhabdomyosarcoma. Genes Chromosome Cancer 1999;26:275–85.

    Article  CAS  Google Scholar 

  16. Sorensen PHB, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2002;20:2672–9.

    Article  PubMed  CAS  Google Scholar 

  17. Lawrence WJ, Gehan EA, Hays DM, et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS II). J Clin Oncol 1987;5:46–54.

    PubMed  Google Scholar 

  18. Lawrence WJ, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer 1997;80:1165–70.

    Article  PubMed  Google Scholar 

  19. Flamant F, Rodary C, Voute PA, Otten J. Primary chemotherapy in the treatment of rhabdomyosarcoma in children: trial of the International Society of Pediatric Oncology (SIOP) preliminary results. Radiother Oncol 1985:3:227–36.

    Article  PubMed  CAS  Google Scholar 

  20. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology MMT84. Eur J Cancer 1998;34:1050–6.

    Article  PubMed  CAS  Google Scholar 

  21. Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment-results of an international workshop. J Clin Oncol 2001;19:197–204.

    PubMed  CAS  Google Scholar 

  22. Stewart RJ, Martelli H, Oberlin O, et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol 2003; 21:793–8.

    Article  PubMed  Google Scholar 

  23. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 1992;15:2557–67.

    Article  Google Scholar 

  24. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999;17:3706–19.

    PubMed  CAS  Google Scholar 

  25. Koscielniak E, Schmidt B, Knietig R, et al. Effectivity of a 32 Gy radiation dose in children with rhabdomyosarcoma: Report of the German Cooperative Soft Tissue Sarcoma Studies (CWS). Med Pediatr Oncol 2001;37:186.

    Google Scholar 

  26. Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 1999;17:3468–75.

    PubMed  CAS  Google Scholar 

  27. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091–102.

    PubMed  CAS  Google Scholar 

  28. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. Am J Pediatr Hematol Oncol 2001;23:215–20.

    Article  CAS  Google Scholar 

  29. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18:2427–34.

    PubMed  CAS  Google Scholar 

  30. Anderson J, Raney RB, Carli M, et al. International study of characteristics and outcome of patients with primary rhabdomyosarcoma of the bladder/prostate. Med Pediatr Oncol 2001;37:181.

    Google Scholar 

  31. Brenemann JC, Lyden E, Pappo AS, e al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma- A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78–84.

    Article  Google Scholar 

  32. Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988;6:308–14.

    PubMed  CAS  Google Scholar 

  33. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group phase II Study. Cancer 1993;71:1898–903.

    Article  PubMed  CAS  Google Scholar 

  34. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001;37:442–8.

    Article  PubMed  CAS  Google Scholar 

  35. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors. A Pediatric Oncology Group phase II Study. J Clin Oncol 2001;19:3463–9.

    PubMed  CAS  Google Scholar 

  36. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796–803.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Oncología Pediátrica, Hospital Universitari Vall d’Hebron, Po Vall d'Hebron, 119, 08035, Barcelona, Spain

    Soledad Gallego Melcón & José Sánchez de Toledo Codina

Authors
  1. Soledad Gallego Melcón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Sánchez de Toledo Codina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soledad Gallego Melcón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melcón, S.G., Codina, J.S.d.T. Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment. Clin Transl Oncol 7, 35–41 (2005). https://doi.org/10.1007/BF02710026

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02710026

Keywords

Search

Navigation